Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANTHEM, INC.

(ANTM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ANTHEM, INC. : Regulation FD Disclosure (form 8-K)

06/04/2021 | 06:09am EDT

Item 7.01 Regulation FD Disclosure.

Officers of Anthem, Inc. (the "Company") will speak with investors over the next several weeks. During these meetings, Company officers intend to reaffirm the Company's net income guidance for full year 2021 to be greater than $24.05 per share, including approximately $1.05 per share of net unfavorable items. Excluding these items, the Company continues to expect adjusted net income to be greater than $25.10 per share. This guidance does not include any other adjustment items beyond those reported in the Company's first quarter 2021 earnings release.

None of the information furnished in Item 7.01 hereto shall be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.

FORWARD-LOOKING STATEMENTS

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as "expect," "feel," "believe," "will," "may," "should," "anticipate," "intend," "estimate," "project," "forecast," "plan" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent otherwise required by federal securities laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof. These risks and uncertainties include, but are not limited to: the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and catastrophes; trends in healthcare costs and utilization rates; our ability to secure sufficient premium rates, including regulatory approval for and implementation of such rates; the impact of federal and state regulation, including ongoing changes in the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the "ACA") and the ultimate outcome of legal challenges to the ACA; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; our ability to contract with providers on cost-effective and competitive terms; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; reduced enrollment; unauthorized disclosure of member or employee sensitive or confidential information, including the impact and outcome of any investigations, inquiries, claims and litigation related thereto; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; risks and uncertainties related to our pharmacy benefit management ("PBM"), business including non-compliance by any party with the PBM services agreement between us

--------------------------------------------------------------------------------

and CaremarkPCS Health, L.L.C.; medical malpractice or professional liability claims or other risks related to healthcare and PBM services provided by our subsidiaries; general risks associated with mergers, acquisitions, joint ventures and strategic alliances; changes in U.S. tax laws; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; failure to effectively maintain and modernize our information systems; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; the impact of international laws and regulations; intense competition to attract and retain employees; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ANTHEM, INC.
07/26INSIDER TRENDS : 90-Day Insider Selling Trend Reduced with Acquisition of Shares..
MT
07/26ANTHEM : Allocates $88 Million to Support Affordable Housing in Indiana
MT
07/24ANTHEM, INC. : Invests in Nearly $90 Million in Affordable Housing in Indiana as..
BU
07/23ANTHEM : Deutsche Bank Adjusts Anthem PT to $408 From $406 on Strong Q2 Results,..
MT
07/22ANTHEM : Strong Q2 Reflects Membership Growth, Below Consensus MLR As RBC Raises..
MT
07/22ANTHEM : Jefferies Adjusts Price Target on Anthem to $453 From $447, Maintains B..
MT
07/22ANTHEM : Mizuho Adjusts Anthem's Price Target to $385 From $380, Maintains Neutr..
MT
07/22ANTHEM : Stephens Adjusts Anthem's Price Target to $440 From $430, Reiterates Ov..
MT
07/22ANTHEM : Price Target From RBC Raised to $408 From $399 After Q2 Beat, 2021 Guid..
MT
07/22ANTHEM : Barclays Adjusts Anthem's Price Target to $450 From $425, Reiterates Ov..
MT
More news
Financials (USD)
Sales 2021 137 B - -
Net income 2021 6 122 M - -
Net Debt 2021 19 675 M - -
P/E ratio 2021 15,5x
Yield 2021 1,11%
Capitalization 93 291 M 93 291 M -
EV / Sales 2021 0,82x
EV / Sales 2022 0,72x
Nbr of Employees 83 400
Free-Float 99,3%
Chart ANTHEM, INC.
Duration : Period :
Anthem, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANTHEM, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 382,63 $
Average target price 428,39 $
Spread / Average Target 12,0%
EPS Revisions
Managers and Directors
Gail Koziara Boudreaux President, Chief Executive Officer & Director
John Edward Gallina Chief Financial Officer & Executive Vice President
Elizabeth E. Tallett Independent Chairman
Gloria M. McCarthy Chief Administrative Officer & Executive VP
Ramiro G. Peru Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ANTHEM, INC.17.88%92 284
UNITEDHEALTH GROUP19.11%390 259
CIGNA CORPORATION9.73%78 388
HUMANA INC.14.86%60 290
CENTENE CORPORATION21.06%42 347
MOLINA HEALTHCARE, INC.21.23%15 057